Search

everythinglearnresearchcommunity

for

Search:↓

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

User experienced hair growth with finasteride and minoxidil, but after using tretinoin, faced aggressive thinning and hair loss. They plan to stop tretinoin for two months to see if the problem improves.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

A user is considering a hair transplant and seeks advice on choosing a clinic, mentioning Spain, Turkey, and the U.S. as options. They are inspired by FC Barcelona goalkeeper ter Stegen's results and are willing to spend up to 50k euros for the best outcome.

Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

The user is experiencing a burning sensation on their scalp despite using finasteride and nizoral for hair loss, and is unsure if they should switch to dutasteride. They have reduced their testosterone dose but the burning persists, and a trichologist suggested it might be telogen effluvium.

Clotrimazole may inhibit testosterone better than Ketoconazole. The user considers applying Clotrimazole cream on the scalp for hair loss.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.

The conversation discusses concerns about importing Koshine KX, a hair loss treatment. A user reassures that there is no risk of getting caught.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

Tretinoin for hair loss in Spain may require a prescription and is often available compounded with minoxidil. Users are discussing how to obtain it.

The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

A female user is experiencing severe hair loss, especially at the crown and front, with broken and dull hair despite using Moroccan oil, shea moisture shampoo, and coconut oil. She seeks recommendations for a clinic or doctor as previous doctors attributed the issue to stress but offered no solutions.

The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

Clascoterone is currently expensive and not yet available for hair loss treatment. The conversation discusses its potential future affordability.